MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1618748

Медицинская библиотека · Frontiers in immunology · 2025

Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.

Gill John, House Andrew A, Chagla Zain, Tchervenkov Jean, Kim S Joseph, Vinson Amanda, Cervera Carlos, Keown Paul A, Sun Sonia Lai Wing, Khoury Christina, Ghakis Christiane

СтатьяПеревод в очереди

Аннотация

PURPOSE: To document prophylactic practices, infection patterns, and disease burden to inform strategies for CMV management in high-risk kidney transplant recipients.

METHODS

A retrospective cohort of 311 consecutive CMV D+/R- kidney recipients were enrolled from 7 Canadian programs over 4 years (2018-2021) to provide data on demographic, clinical, therapeutic and health resource use during the 1st year post-transplant.

RESULTS

Themedian age was 58 (46, 67) years, 69% were male, and 53% were White. Diabetes was the principal cause of kidney failure (19%). 208 (69%) received a deceased donor graft; 76 (24%) had ATG induction, and 84% had maintenance therapy with tacrolimus and MMF/MPA ± prednisone. All received antiviral prophylaxis, 90% with valganciclovir, for a median of 180 days. 106 (34%) developed CMV viremia (median peak viral load 14,224 IU/ml) at a median of 218 days, of whom 46 (43%) had CMV disease and 15 (14%) had recurrent infection. Myelotoxicity occurred in 121 (39%) patients at a median of 88 days, lasting a median of 30 days. Opportunistic infections occurred in 119 patients (38%) at a median of 53 days. 141 patients (45%) were hospitalized, 50 (16%) more than once. 20 patients (6%) had biopsy-confirmed rejection, and 293 (94%) were alive with a functioning graft at 1 year.

CONCLUSION

Current prophylaxis strategies fail to prevent CMV infection in 34% of high-risk patients. Myelotoxicity, opportunistic infection, reduced immunosuppression, and hospitalization remain common and serious complications. More effective and less toxic personalized treatment strategies are required to minimize these risks and burdens.

Для цитирования: Gill John, House Andrew A, Chagla Zain, Tchervenkov Jean, Kim S Joseph, Vinson Amanda, Cervera Carlos, Keown Paul A, Sun Sonia Lai Wing, Khoury Christina, Ghakis Christiane. Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1618748.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.